Valion Bio, Inc.

Revenue net of returns was $140,000 in the third quarter of 2025, up from $126,000 a year ago; nine-month revenue was $302,000 versus $600,000 in 2024. Cost of sales was $291,000 in the quarter versus $82,000 last year, mainly due to a $230,000 inventory reserve; gross margin excluding that reserve was 42% versus 35% a year ago. Operating expenses were $2.3 million versus $1.5 million, and net loss was $2.6 million versus $1.4 million. For the first nine months, operating expenses were $5.9 million versus $4.4 million and net loss was $6.0 million versus $4.2 million. Cash and cash equivalents were $3.5 million at 09/30/2025 versus $2.0 million at 12/31/2024, and management said remaining preferred purchase agreement tranches should help fund GMP manufacturing validation for entolimod.

Jennifer Ernst framed the quarter as part of a broader company reset from bioelectronics to biologics centered on the immune system. She emphasized progress on entolimod, including IND transfers, manufacturing readiness, and discussions with BARDA and other government stakeholders about acute radiation syndrome stockpiling. On VNS, she said the optimization data were stronger and more surprising than expected, and that the company is evaluating alternative commercial opportunities because the findings may broaden the program’s potential.

Lisa Wolf said the quarter’s numbers reflect the shift away from consumer devices and toward the biopharmaceutical strategy. She highlighted a $230,000 inventory reserve in cost of goods sold and a $117,000 write-off of ClearUp-related assets, while noting the company does not expect additional significant exit costs. She pointed to $3.5 million in cash and cash equivalents, no debt, and said remaining planned tranches of the preferred purchase agreement should support progress toward GMP manufacturing validation for entolimod.

There was no traditional analyst Q&A in the transcript; the call was a prerecorded update with no external questions. Management’s main implied answers were around why costs rose, why revenue was still small, and whether the company had enough resources: they attributed expense growth to biologics R&D and said the balance sheet, plus financing tranches, should fund near-term manufacturing milestones. On the strategic side, they also signaled that VNS may need a revised commercial strategy after unexpected optimization results.